𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer

✍ Scribed by Joshua O. Atiba; Stephanie J. Green; Harry E. Hynes; C. Kent Osborne; Thomas P. Miller; Mark Davidner

Publisher
Springer US
Year
1994
Tongue
English
Weight
266 KB
Volume
12
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Doxorubicin, vincristine, and cis-diammi
Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer
✍ Trump, Donald L. ;Ettinger, David S. ;Abeloff, Martin D. πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 151 KB

## Abstract Preliminary data suggesting synergistic activity of cisplatinum and doxorubicin and the expected poor prognosis of women with breast cancer who progress on treatment with cyclophosphamide, methotrexate and 5‐fluorouracil (CMF), led to a trial of monthly doxorubicin (50 mg/M^2^), vincris

Phase II studies of mitoxantrone in pati
Phase II studies of mitoxantrone in patients with primary liver cancer
✍ Geoffrey Falkson; Barend Johannes Coetzer πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 147 KB

Forty-nine patients with histologically conlirmed primary liver cancer have been entered on phase II trials of mitoxantrone (NovantroneC"~; dihydroxyanthracenedione), at a dose of 14 mg/m 2 every 3 weeks. Among the patients evaluable for toxicity, leukopenia and thrombocytopenia were the most import